These Are the Big Funds That Were Slammed in Biotech's RoutBy and
Diversified funds heavy in biotech down 3.8% since rout began
Fidelity, JPMorgan funds show recent losses on paper
It’s not just biotechnology specialists who have been hit by the slide in drug stocks.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.